Cost-effectiveness of using clinical risk factors with and without DXA for osteoporosis screening in postmenopausal women

Value in Health

Volumn 12, Issue 8, 2009, Pages 1106-1117

  Mueller, Dirk ^a   Econ, Health ^a   Gandjour, Afschin ^b  

^a UNIVERSITY OF COLOGNE   (Germany)

^b RICE UNIVERSITY   (United States)

Author keywords

Cost utility analysis; Modeling; Osteoporosis; Secondary prevention; Women's health

Indexed keywords

ADULT; AGED; ARTICLE; BONE DENSITY; COHORT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FRACTURE; HEALTH INSURANCE; HUMAN; MAJOR CLINICAL STUDY; POSTMENOPAUSE OSTEOPOROSIS; PREDICTION; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; RISK FACTOR; SCREENING; SECONDARY PREVENTION;

EID: 70350752318     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2009.00577.x     Document Type: Article

References (78)

1. Ribot C, Tremollieres F, Pouilles JM. Can we detect women with low bone mass using clinical risk factors? Am J Med 1995 98 (2A 52S 55S.
2. Cummings SR, Bates D, Black DM. Clinical use of bone densitometry. JAMA 2002 288 : 1889 97.
3. WHO Study Group. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. World Health Organ Tech Rep Ser 1994 843 : 1 129.
4. Kanis JA, Oden A, Johnell O. The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int 2007 18 : 1033 46.
5. Bolotin HH, Sievanen H. Inaccuracies inherent in dual-energy x-ray absorptiometry in vivo bone mineral density can seriously mislead diagnostic/prognostic interpretations of patient-specific bone fragility. J Bone Miner Res 2001 16 : 799 805. (Pubitemid 32332289)
6. Nelson HD, Helfand M, Woolf SH, et al. Screening for postmenopausal osteoporosis: a review of the evidence for the US Preventive Services Task Force. Ann Intern Med 2002 137 : 529 41.
7. German Osteology Umbrella Organization DVO. Prophylaxe, Diagnostik und Therapie der Osteoporose. S3-Leitlinie des Dachverbandes der deutschsprachigen wissenschaftlichen osteologischen Gesellschaften. 2006. Available from: http://www.dv-osteologie.org/uploads/leitlinien/ Langfassung%20DVO%20Leitlinie%2011-05-06.pdf [Accessed February 20, 2009].
8. Institute for Quality and Efficiency in Health Care. Osteodensitometrie bei primärer und sekundärer Osteoporose. Berichtsplan. Available from: http://www.iqwig.de/download/D07-01-Berichtsplan-V-2-0-Osteodensitometrie-bei- primaerer-und-sekundaerer-Osteoporose.pdf [Accessed February 20, 2009].
9. World Health Organization (WHO). FRAX: WHO fracture risk assessment tool. Available from: http://www.shef.ac.uk/FRAX/index.htm [Accessed November 14, 2008].
10. Cadarette SM, Jaglal SB, Murray TM, et al. Evaluation of decision rules of referring women for bone densitometry by dual-energy x-ray absorptiometry. JAMA 2001 286 : 57 63.
11. Marshall D, Johnell O, Wedel H, et al. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996 312 : 1254 9.
12. Schwartz EN, Steinberg DM. Prescreening tools to determine who needs DXA. Curr Osteoporos Rep 2006 4 : 148 52.
13. Kanis JA, Johnell O, Oden A, et al. Ten-year risk of osteoporotic fracture and the effect of risk factors on screening strategies. Bone 2002 30 : 251 8.
14. De Laet C, Oden A, Johansson H, et al. The impact of the use of multiple risk indicators for fracture on case-finding strategies: a mathematical approach. Osteoporos Int 2005 16 : 313 8.
15. National Osteoporosis Foundation. NOF's new clinician's guide to prevention and treatment of osteoporosis. Available from: http://www.nof.org/ professionals/NOF-Clinicians-Guide.pdf [Accessed April 21, 2008].
16. National Institute for Health and Clinical Excellence. Osteoporosis - secondary prevention. The clinical effectiveness of technologies for the secondary prevention of osteoporotic fractures in postmenopausal women. Available from: http://www.nice.org.uk/guidance/index.jsp?action=byID&o= 11550 [Accessed December, 2008].
17. Fleurence RL, Iglesias CP, Johnson JM. The cost effectiveness of bisphosphonates for the prevention and treatment of osteoporosis: a structured review of the literature. Pharmacoeconomics 2007 25 : 913 33.
18. Richy F, Ethgen O, Bruyere O, et al. Primary screening of osteoporosis: mass screening or prescreening with questionnaires). An economic perspective. J Bone Miner Res 2004 19 : 1955 60.
19. van Staa TP, Kanis JA, Geusens P, et al. The cost-effectiveness of bisphosphonates in postmenopausal women based on individual long-term fracture risks. Value Health 2007 10 : 348 57.
20. Stevenson M, Davis S, Lloyd-Jones M, et al. The clinical effectiveness and cost-effectiveness of strontium ranelate for the prevention of osteoporotic fragility fractures in postmenopausal women. Health Technol Assess 2007 11 : 1 134.
21. Stevenson MD, Brazier JE, Calvert NW, et al. Description of an individual patient methodology for calculating the cost-effectiveness of treatments for osteoporosis in women. J Oper Res Soc 2005 56 : 214 21.
22. Mueller D, Weyler E, Gandjour A. Cost effectiveness of the German screen-and-treat strategy for postmenopausal osteoporosis. Pharmacoeconomics 2008 26 (6 513 36.
23. Gold MR, Siegel JE, Russell LB, et al. Cost-Effectiveness in Health and Medicine. New York : Oxford University Press, 1996.
24. Bundeszentrale für Politische Bildung (BPB). Krankenversicherungsschutz der Bevölkerung. Available from: http://www.bpb.de/files/LQ7Y05.pdf [Accessed December 13, 2008].
25. Zentralinstitut für Kassenärztliche Versorgung. ZIADT-Panel Nordrhein, Patienten- / Praxisstichprobe: IV. 2005. Available from: http://www.zi-berlin.de/morbilitaetsanalyse/ergebnisse-panel.php [Accessed December 13, 2008].
26. Mauskopf JA, Sullivan SD, Annemans L, et al. Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices - budget impact analysis. Value Health 2007 10 : 336 47.
27. Federal Statistical Office (Germany). Sterbefälle. Available from: http://www.destatis.de/jetspeed/portal/cms/Sites/destatis/Internet/DE/Content/ Statistiken/Bevoelkerung/GeburtenSterbefaelle/Tabellen/Content100/ SterbetafelDeutschland,property=file.xls [Accessed December 13, 2008].
28. Weinstein MC, Siegel JE, Gold MR, et al. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA 1996 16 : 1253 8.
29. Federal Statistical Office (Gernany). Consumer Price Index for Germany. Available from: http://www.destatis.de/jetspeed/portal/cms/Sites/destatis/ Internet/DE/Navigation/Statistiken/Preise/Verbraucherpreise/Verbraucherpreise, templateId=renderPrint.psml-nnn=true [Accessed December 13, 2008].
30. Zethraeus N, Borgström F, Ström O, et al. Cost-effectiveness of the treatment and prevention of osteoporosis - a review of the literature and a reference model. Osteoporos Int 2007 18 : 9 23.
31. Stevenson M, Jones ML, De Nigris E, et al. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis. Health Technol Assess 2005 9 : 1 160.
32. Tosteson ANA, Jönsson B, Grima DT, et al. Challenges for model-based economic evaluations of post-menopausal osteoporosis interventions. Osteoporos Int 2001 12 : 849 57.
33. Cramer JA, Roy A, Burrel A, et al. Medication compliance and persistence: terminology and definitions. Value Health 2008 11 : 44 7.
34. Bartl R, Götte S, Hadji P, et al. Adherence with daily and weekly administration of oral bisphosphonates for osteoporosis. Dtsch Med Wochenschr 2006 131 : 1257 62.
35. O'Neill TW, Felsenberg D, Varlow J, et al. The prevalence of vertebral deformity in European men and women: The European Vertebral Osteoporosis Study. J Bone Miner Res 1996 11 : 1010 8.
36. van der Klift M, DeLaet CE. The incidence of vertebral fractures in men and women: The Rotterdam Study. J Bone Miner Res 2002 17 : 1051 6.
37. Federal Statistical Office (Germany). Diagnosedaten der Krankenhauspatientinnen u. patienten (einschl. Sterbe- u. Stundenfälle) Fachserie 12 Reihe 6.2.1. Available from: https://www-ec.destatis.de/csp/shop/ sfg/bpm.html.cms.cBroker.cls?cmspath=struktur,vollanzeige.csp&ID=1023509 [Accessed December 8, 2008].
38. Felsenberg D, Silman AJ, Lunt M, et al. Incidence of vertebral fracture in Europe: results from the European Prospective Osteoporosis Study. J Bone Miner Res 2002 17 : 716 23.
39. Singer BR, Mclauchlan GJ, Robinson CM, et al. Epidemiology of fractures in 15.000 adults. The influence of age and gender. J Bone Joint Surg Br 1998 80 : 243 8.
40. Center JR, Bliuc D, Nguyen TV, et al. Risk of subsequent fracture after low-trauma fracture in men and women. JAMA 2007 297 : 387 94.
41. Federal Statistical Office (Germany). Bevölkerung nach Altersgruppen, Familienstand und Religionszugehörigkeit. Available from: http://www.destatis.de/jetspeed/portal/cms/Sites/destatis/Internet/DE/Content/ Statistiken/Bevoelkerung/GeburtenSterbefaelle/Tabellen/Content100/ SterbetafelFBNL,property=file.xls [Accessed November 9, 2008].
42. Browner WS, Seeley DG, Vogt TM, et al. Non-trauma mortality in elderly women with low bone mineral density. Lancet 1991 338 : 355 8.
43. Center JR, Nguyen TV, Schneider D, et al. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 1999 353 : 872 82.
44. Kado DM, Browner WS, Palermo L, et al. Vertebral fractures and mortality in older women. Arch Intern Med 1999 159 : 1215 20.
45. Gandjour A, Weyler EJ. Cost-effectiveness of referrals to high-volume hospitals: an analysis based on a probabilistic Markov model for hip fracture surgeries. Health Care Manag Sci 2006 9 : 359 69.
46. Wenning M, Hupe K, Scheuer I, et al. Does quantity mean quality? An analysis of 116,000 patients regarding the connection between the number of cases and the quality of results. Chirurg 2000 71 : 717 22.
47. Tidermark J, Zethraeus N, Svensson O, et al. Femoral neck fractures in the elderly: functional outcome and quality of life according to EuroQol. Qual Life Res 2002 11 : 473 81.
48. Brazier JE, Green C, Kanis JA. A systematic review of health state utility values for osteoporosis-related conditions. Osteoporos Int 2002 13 : 768 76.
49. Kanis JA, Johnell O, Oden A. The risk and burden of vertebral fractures in Sweden. Osteoporos Int 2004 15 : 20 6.
50. Deutsche Gesellschaft für Allgemein- und Familienmedizin. Kreuzschmerzen. 2003. Available from: http://www.degam.de/leitlinien/LL-Kreuz- Internet.pdf [Accessed January 14, 2009].
51. Neuhauser H, Ellert U, Ziese T. Chronic back pain in the general population in Germany 2002/2003: prevalence and higly affected population groups. Gesundheitswesen 2005 67 : 685 93.
52. PMV Research Group. Versorgungssituation von Patienten mit chronisch lumbalen Rückenschmerzen. Available from: http://www.pmvforschungsgruppe. de/content/02-forschung/02-c-versorgungsf-10.htm [Accessed January 14, 2009].
53. Cooper C, Atkinson EJ, O'Fallon WM, et al. Incidence of clinically diagnosed vertebral fractures: a population-based study in Rochester, Minnesota 1985-1989. J Bone Miner Res 1992 7 : 221 7.
54. Delmas PD, van de Langerijt L, Watts NB, et al. Underdiagnosis of vertebral fractures is a worldwide problem: the IMPACT study. J Bone Miner Res 2005 557 63.
55. National Osteoporosis Foundation. Osteoporosis: review of the evidence for prevention, diagnosis and treatment and cost-effectiveness analysis. Osteoporosis Int 1998 8 (Suppl. 4 S7 80.
56. Cummings SR, Nevitt MC, Browner WS, et al. Risk factors for hip fracture in white women. N Engl J Med 1995 332 : 767 73.
57. Uniform Value Scale. 2006. Available from: http://www.ebm2000plus.de/ EBMGesamt.htm [Accessed December 11, 2008].
58. German Red List. 2006 Available from: http://www.rote-liste.de [Accessed December 11, 2008].
59. Physio. de Informationsdienste GmbH. Catalogue of non-physician treatments. 2004. Available from: http://www.heilmittelkatalog.de [Accessed December 19, 2008].
60. Physio. de Informationsdienste GmbH. Price lists. Available from: http://www.physio.de/preislisten/index.php?mode=0&PHPSESSID= 188e9d915ddd0df45f16ab93237473fe [Accessed January 19, 2009].
61. Institut für das Entgeltsystem im Krankenhaus. Fallpauschalenkatalog. Available from: http://www.g-drg.de/cms/index.php/inek- site-de/Archiv/Systemjahr-2006-bzw.-Datenjahr-2004#sm2 [Accessed January 28, 2009].
62. Institut für das Entgeltsystem im Krankenhaus. Abschlussbericht zur Weiterentwicklung des G-DRG- Systems für das Jahr. Klassifikation, Katalog und Bewertungsrelationen. Band II: Fallpauschalenkatalog, klinische Profile. Kostenprofile. Available from: http://www.g-drg.de/cms/index.php/inek-site-de/ Archiv/Systemjahr-2004-bzw.-Datenjahr-2002#sm7 [Accessed January 28, 2009].
63. Federal Statistical Office (Germany). Krankheitskosten 2002, 2004 und 2006. Available from: https://www-ec.destatis.de/csp/shop/sfg/bpm.html.cms. cBroker.cls?cmspath=struktur,vollanzeige.csp&ID=1022498 [Accessed October 7, 2008].
64. Melton LJ, Thamer M, Ray NF, et al. Fractures attributable to osteoporosis: report from the National Osteoporosis Foundation. J Bone Miner Res 1997 12 : 16 23.
65. Frybeck DG, Chinnis JO, Ulvila JW. Bayesian cost effectiveness analysis. An example using the GUSTO trial. Int J Technol Assess Health Care 2001 17 : 83 97.
66. Stinnett AA, Mullahy J. Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Med Dec Making 1998 18 (Suppl. S65 80.
67. Federal Statistical Office (Germany). Health in Germany. Available from: http://www.gbe-bund.de/gbe10/owards.prc-show-pdf?p-id=9965&p-sprache= E&p-uid=gastd&p-aid=68474622&p-lfd-nr=1 [Accessed January 14, 2009].
68. Gandjour A, Stock S. A national hypertension treatment program in Germany and its estimated impact on costs, life expectancy, and cost-effectiveness. Health Policy 2007 83 : 257 67.
69. Schousboe JT. Cost-effectiveness modeling research of pharmacologic therapy to prevent osteoporosis-related fractures. Curr Rheumatol Rep 2007 9 : 50 6.
70. Briggs A, Sculpher M. An introduction to Markov modelling for economic evaluation. Pharmacoeconomics 1998 13 : 397 409.
71. Häussler B, Gothe H, Göl D. Epidemiology, treatment and costs of osteoporosis in Germany - the bone EVA study. Osteoporos Int 2007 18 : 77 84.
72. Stevenson MD, Oakley J, Chilcott JB. Gaussian process modeling in conjunction with individual patient simulation modeling: a case study describing the calculation of cost-effectiveness ratios for the treatment of established osteoporosis. Med Decis Making 2004 24 : 89 100.
73. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999 13 : 1344 52.
74. Kanis JA, Barton IP, Johnell O. Risedronate decreases fracture risk in patients selected solely on the basis of prior vertebral fracture. Osteoporos Int 2005 16 : 475 82.
75. Reginster JY, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral efficacy with risedronate therapy (VERT) study group. Osteoporos Int 2000 11 : 83 91.
76. Saag KG, Emkey R, Schnitzer TJ, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med 1998 30 : 292 9.
77. Adachi JD, Saag KG, Delmas PD, et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum 2001 44 : 202 11.
78. Federal Statistical Office Germany. Statistisches Jahrbuch. Available from: http://www.destatis.de/jetspeed/portal/cms/Sites/destatis/Internet/DE/ Content/Statistiken/Arbeitsmarkt/Sozialversicherungspflichtige/Tabellen/ Content50/Altersgruppen,templateId=renderPrint.psml [Accessed April 20, 2008].